Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2023

Bimekizumab Treatment in Patients With Active Axial Spondyloarthritis: 52-week Efficacy and Safety from the Randomised Parallel Phase 3 BE MOBILE 1 and BE MOBILE 2 Studies

Ann Rheum Dis. 2023;83(2):199–213 doi 10.1136/ard-2023-224803

Xu H,

Vaux T,

Baraliakos, et al. present data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, that investigated the clinical efficacy and safety of bimekizumab in axSpA patients. They found that bimekizumab had sustained and consistent efficacy in patients with nr-axSpA and r-axSpA.

Keywords:

August 2023

Long-Term Safety and Efficacy of Ixekizumab in Patients with Axial Spondyloarthritis: 3-year Data from the COAST Program

J Rheumatol. 2023;50(8):1020–1028 doi: 10.3899/jrheum.221022

Bolce R,

Leung A,

Three-year data from the ixekizumab (IXE) COAST programme provide additional evidence that patients with axSpA receiving IXE experience long-term safety, and sustained improvements in efficacy outcomes, at 3 years.

Keywords:

February 2023

Efficacy and Safety of Bimekizumab in Axial Spondyloarthritis: Results of Two Parallel Phase 3 Randomised Controlled Trials

Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595

Vaux T,

Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.

Keywords:

September 2022

Efficacy and Safety of Ixekizumab Treatment in Patients with Axial Spondyloarthritis: 2-year Results from COAST

RMD Open. 2022 doi: 10.1136/rmdopen-2021-002165

Braun J,

Kiltz U,

Bolce R,

Lin CY,

This study highlighted improvements in disease activity, function and quality of life were achieved early on into treatment and were sustained through 116 weeks of IXE therapy for patients with r-axSpA and nr-axSpA. In this study investigators aimed to report the long-term efficacy and safety results for patients treated with ixekizumab for up to 116 weeks.